Clinical Trial Update: Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients [Phase 2, Phase 3]

View source ↗

Summary

A multicentre Phase 2/Phase 3 trial evaluating Abagovomab as an immunotherapy vaccine for ovarian cancer has been terminated; results were posted in November 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Abagovomab

Snippet

Sponsor: Menarini Group | Conditions: Ovarian Cancer | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2011-11-18